Tag Archives: Dicerna

October, 2018

  • 30 October

    Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

    INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC™ RNAi technology platform …

  • 24 October

    Alexion and Dicerna Collaborate to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

    BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN) and Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases. An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases. …